BIOMAT Database Logo BIOMAT Database Logo

Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study. 1975

B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
May 1976, Cancer treatment reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer.
January 1975, Cancer chemotherapy reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
January 1976, Cancer treatment reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
January 1975, Cancer chemotherapy reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
December 1978, Cancer,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease.
April 1970, Cancer chemotherapy reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
October 1970, Cancer research,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
January 1974, Cancer chemotherapy reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation.
May 1976, Cancer treatment reports,
B L Tranum, and R L Stephens, and D E Lehane, and B Hoogstraten, and M Lane, and A Haut
Letter: Cardiotoxicity of 5-fluorouracil (NSC-19893)
January 1975, Cancer chemotherapy reports,
Copied contents to your clipboard!